Company intelligence

PCSA

Processa Pharmaceuticals, Inc. · NASDAQ · Healthcare

Price$2.13-2.29% · −$0.05

Market cap5.9MEquity value

P / E-0.1Trailing ratio

Volume21.56KLatest session

Market data

PCSA price chart

TradingView

Related signals

1 min delayed

Browse public PCSA signals with their source context and measured market impact. Open any signal for its permanent analysis page.

PCSAJul 29, 2026-32.13% since signal

Processa to Acquire Vidya Therapeutics, Expanding Immune-Targeted Pipeline

Processa announced an all-stock acquisition of Vidya Therapeutics, gaining access to its lead candidate aimed at immune-system diseases. The deal expands PCSA's pipeline but introduces dilution risk from share issuance and integration execution. If Vidya's program advances with favorable data, PCSA could realize meaningful valuation upside in the next 12-24 months.

View signal analysis

PCSADec 17, 2025-40.32% since signal

Why Is Small-Cap Processa Pharmaceuticals Stock Rallying After Breast Cancer Trial Data?

PCSA stock increased by 130.95% to $6.94. NGC-Cap treatment shows better efficacy with fewer side effects. Clinical study involves 19 patients, assessing safety and efficacy. FBAL exposure significantly lower with NGC-Cap compared to standard therapy. Final patient enrollment for analysis expected by Q1 2026.

View signal analysis

Research